Plasma phosphorylated tau 181 predicts amyloid status and conversion to dementia stage dependent on renal function.

ABSTRACT:

Objectives

Plasma P-tau181 is an increasingly established diagnostic marker for Alzheimer's disease (AD). Further validation in prospective cohorts is still needed, as well as the study of confounding factors that could influence its blood level.

Methods

This study is ancillary to the prospective multicentre Biomarker of AmyLoid pepTide and AlZheimer's diseAse Risk cohort that enrolled participants with mild cognitive impairment (MCI) who were examined for conversion to dementia for up to 3 years. Plasma Ptau-181 was measured using the ultrasensitive Quanterix HD-X assay.

Results

Among 476 MCI participants, 67% were amyloid positive (Aβ+) at baseline and 30% developed dementia. Plasma P-tau181 was higher in the Aβ+ population (3.9 (SD 1.4) vs 2.6 (SD 1.4) pg/mL) and i

SUBMITTER: Lehmann S 

PROVIDER: S-EPMC10314000 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature